1-(1-(4-pyridyl)piperidin-4-ylcarbonyl)piperazine | 179051-74-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(1-(4-pyridyl)piperidin-4-ylcarbonyl)piperazine
• 英文别名: 1-[1-(pyridin-4-yl)piperidin-4-ylcarbonyl]piperazine；1-(4-Pyridylpiperidin-4-ylcarbonyl)piperazine；piperazin-1-yl-(1-pyridin-4-ylpiperidin-4-yl)methanone
• CAS: 179051-74-2
• 化学式: C₁₅H₂₂N₄O
• 分子量: 274.366
• InChiKey: KTXCOBVGGZETQY-UHFFFAOYSA-N

物化性质

• 熔点：
  131-132 °C
• 沸点：
  491.7±45.0 °C(Predicted)
• 密度：
  1.163±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  48.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-溴苯磺酰氯 、 1-(1-(4-pyridyl)piperidin-4-ylcarbonyl)piperazine 在 吡啶 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 [4-(3-Bromo-benzenesulfonyl)-piperazin-1-yl]-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
  参考文献：
  名称：

  A Novel Series of 4-Piperidinopyridine and 4-Piperidinopyrimidine Inhibitors of 2,3-Oxidosqualene Cyclase−Lanosterol Synthase

  摘要：

  A novel series of 4-piperidinopyridines and 4-piperidinopyrimidines showed potent and selective inhibition of rat 2,3-oxidosqualene cyclase-lanosterol synthase (OSC) (e.g. 26 IC50 rat = 398 +/- 25 nM, human = 112 +/- 25 nM) and gave selective oral inhibition of rat cholesterol biosynthesis (26 ED80 = 1.2 +/- 0.3 mg/kg, n = 5; HMGCoA reductase inhibitor simvastatin, ED80 = 1.2 +/- 0.3 mg/kg, n = 5). The piperidinopyrimidine OSC inhibitors have a significantly lower pK(a) than the corresponding pyridine or the previously reported quinuclidine OSC inhibitor series. This indicates that other novel OSC inhibitors may be found in analogues of this series across a broader pK(a) range (6.0-9.0). These series may yield novel hypocholesterolemic agents for the treatment of cardiovascular disease.

  DOI：

  10.1021/jm000139k
• 作为产物：
  描述：

  1-(4-pyridinyl)piperidin-4-yl carbonyl chloride 在 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 生成 1-(1-(4-pyridyl)piperidin-4-ylcarbonyl)piperazine
  参考文献：
  名称：

  A Novel Series of 4-Piperidinopyridine and 4-Piperidinopyrimidine Inhibitors of 2,3-Oxidosqualene Cyclase−Lanosterol Synthase

  摘要：

  A novel series of 4-piperidinopyridines and 4-piperidinopyrimidines showed potent and selective inhibition of rat 2,3-oxidosqualene cyclase-lanosterol synthase (OSC) (e.g. 26 IC50 rat = 398 +/- 25 nM, human = 112 +/- 25 nM) and gave selective oral inhibition of rat cholesterol biosynthesis (26 ED80 = 1.2 +/- 0.3 mg/kg, n = 5; HMGCoA reductase inhibitor simvastatin, ED80 = 1.2 +/- 0.3 mg/kg, n = 5). The piperidinopyrimidine OSC inhibitors have a significantly lower pK(a) than the corresponding pyridine or the previously reported quinuclidine OSC inhibitor series. This indicates that other novel OSC inhibitors may be found in analogues of this series across a broader pK(a) range (6.0-9.0). These series may yield novel hypocholesterolemic agents for the treatment of cardiovascular disease.

  DOI：

  10.1021/jm000139k

文献信息

• Aminoheterocyclic derivatives as antithrombotic or anticoagulant
  申请人：Zeneca Limited

  公开号：US05965559A1

  公开（公告）日：1999-10-12

  The invention concerns compounds of formula (I), wherein each of G.sup.1, G.sup.2 and G.sup.6 is CH or n; m is 1 or 2; R.sup.1 includes hydrogen, halogeno and (1-4C)alkyl; M.sup.1 is a group of formula: NR.sup.2 -L.sup.1 -T.sup.1 R.sup.3, in which R.sup.2 and R.sup.3 together form a (1-4C)alkylene group, L.sup.1 includes (1-4C)alkylene, and T.sup.1 is CH or N; A may be a direct link; M.sup.2 is a group of the formula: (T.sup.2 R.sup.4).sub.r -L.sup.2 T.sup.3 R.sup.5 in which R is 0 or 1, each of T.sup.2 and T.sup.3 is CH or N, each of R.sup.4 and R.sup.5 is hydrogen or (1-4C)alkyl, or R.sup.4 and R.sup.5 together form a (1-4C)alkylene group, and L.sup.2 includes (1-4C)alkylene; M.sup.3 may be a direct link to X; X includes sulphonyl; and Q includes naphthyl and a heterocycle moiety; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use as antithrombotic or anticoagulant agents.

  该发明涉及式(I)的化合物，其中G.sup.1、G.sup.2和G.sup.6中的每一个是CH或n；m为1或2；R.sup.1包括氢、卤代和(1-4C)烷基；M.sup.1是式的一个基团：NR.sup.2 -L.sup.1 -T.sup.1 R.sup.3，在其中R.sup.2和R.sup.3共同形成一个(1-4C)烷基基团，L.sup.1包括(1-4C)烷基，T.sup.1为CH或N；A可以是直接连接；M.sup.2是式的一个基团：(T.sup.2 R.sup.4).sub.r -L.sup.2 T.sup.3 R.sup.5，在其中R为0或1，T.sup.2和T.sup.3中的每一个是CH或N，R.sup.4和R.sup.5中的每一个是氢或(1-4C)烷基，或R.sup.4和R.sup.5共同形成一个(1-4C)烷基基团，L.sup.2包括(1-4C)烷基；M.sup.3可以是到X的直接连接；X包括磺酰基；Q包括萘基和杂环基；或其药学上可接受的盐；它们的制备方法，含有它们的药物组合物以及它们作为抗血栓或抗凝血剂的用途。
• Use of oxido-squalene cyclase inhibitors to lower blood cholesterol
  申请人：Zeneca Limited

  公开号：US06090813A1

  公开（公告）日：2000-07-18

  A compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein G, T.sup.1, T.sup.2 and T.sup.3 are selected from CH and N; provided that T.sup.2 and T.sup.3 are not both CH; A is selected from a direct bond and (1-4C)alkylene; X is selected from oxy, thio, sulphinyl, sulphonyl, carbonyl, carbonylamino, N-di-(1-6C)alkylcarbonylamino, sulphonamido, methylene, (1-4C)alkylmethylene and di-(1-6C)alkylmethylene, and when T.sup.2 is CH, X may also be selected from aminosulphonyl and oxycarbonyl; and Q is selected from (5-7C)cycloalkyl, a heterocyclic moiety containing up to 4 heteroatoms selected from nitrogen, oxygen and sulphur, phenyl, naphthyl, phenyl(1-4C)alkyl and phenyl(2-6C)alkenyl; for the manufacture of a medicament for treating diseases or medical conditions in which an inhibition of oxido-squalene cyclase is desirable. ##STR1##

  化合物的结构式（I），或其药学上可接受的盐，其中G、T.sup.1、T.sup.2和T.sup.3选自CH和N；但要求T.sup.2和T.sup.3不能同时为CH；A选自直链键和（1-4C）烷基；X选自氧、硫、亚砜、磺酰、羰基、羰胺基、N-二（1-6C）烷基羰胺基、磺酰胺基、亚甲基、（1-4C）烷基亚甲基和二（1-6C）烷基亚甲基，当T.sup.2为CH时，X还可选自氨基磺酰和氧羰基；Q选自（5-7C）环烷基、含有最多4个氮、氧和硫杂原子的杂环基团、苯基、萘基、苯基（1-4C）烷基和苯基（2-6C）烯基；用于制备一种治疗需要氧化-角鲨烯环化酶抑制的药物，用于治疗疾病或医疗状况。
• Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents
  申请人：ZENECA LIMITED

  公开号：US20020119968A1

  公开（公告）日：2002-08-29

  The invention concerns compounds of formula (I) 1 wherein each of G 1 , G 2 and G 3 is CH or N; m is 1 or 2; R 1 includes hydrogen, halogeno and (1-4C)alkyl; M 1 is a group of the formula: NR 2 —L 1 —T 1 R 3 in which R 2 and R 3 together form a (1-4C)alkylene group, L 1 includes (1-4C)alkylene, and T 1 is CH or N; A may be a direct link; M 2 is a group of the formula: (T 2 R 4 ) r —L 2 —T 3 R 5 in which r is 0 or 1, each of T 2 and T 3 is CH or N, each of R 4 and R 5 is hydrogen or (1-4C)alkyl, or R 4 and R 5 together form a (1-4C)alkylene group, and L 2 includes (1-4C)alkylene; M 3 may be a direct link to X; X includes sulphonyl; and Q includes naphthyl and a heterocyclic moiety; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use as antithrombotic or anticoagulant agents.

  本发明涉及式(I)的化合物，其中G1、G2和G3中的每一个是CH或N；m为1或2；R1包括氢、卤素和(1-4C)烷基；M1是公式NR2-L1-T1R3的基团，在其中R2和R3共同形成一个(1-4C)烷基，L1包括(1-4C)烷基，T1是CH或N；A可以是直接连接；M2是公式(T2R4)r-L2-T3R5的基团，在其中r为0或1，T2和T3中的每一个是CH或N，R4和R5中的每一个是氢或(1-4C)烷基，或者R4和R5共同形成一个(1-4C)烷基，L2包括(1-4C)烷基；M3可以是直接连接到X；X包括磺酰基；Q包括萘基和杂环基；或其药学上可接受的盐；制备它们的方法，含有它们的制药组合物以及它们作为抗血栓或抗凝剂剂的用途。
• AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS
  申请人：ZENECA LIMITED

  公开号：EP0783500B1

  公开（公告）日：1998-07-22
• USE OF OXIDO-SQUALENE CYCLASE INHIBITORS TO LOWER BLOOD CHOLESTEROL
  申请人：ZENECA LIMITED

  公开号：EP0844877A1

  公开（公告）日：1998-06-03